Oxford Spin-Out OMass Raises $298M to Push Small-Molecule Drugs Closer to Patients

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech spun out of Oxford, just closed an oversubscribed $298 million (€275 million) Series C round. The company is developing small-molecule drugs against tricky targets that have historically been hard to drug. This cash injection will push their lead program into mid-stage clinical trials. The round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings. They were joined by Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. All existing investors also participated, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. That's a serious vote of confidence from a top-tier syndicate. ### Why This Matters for Patients OMass isn't just another biotech. They're going after validated target ecosystems that have been tough to crack with traditional small molecules. Their proprietary OdyssION platform combines native mass spectrometry, novel biochemistry, and custom chemistry to study drug targets in their native environments. Think of it as getting cell-system fidelity with cell-free precision. That means they can design drugs that are more likely to work in the real world, not just in a lab dish. "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow," said Ros Deegan, CEO of OMass Therapeutics. "We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic." ### A Rising Tide of European Biotech Funding OMass' round is part of a broader surge in European therapeutics financing. In 2026 alone, we've seen: - France's Bionyra Pharma securing $155 million for inflammatory disease treatments - Denmark's Breye Therapeutics raising $73 million for oral small-molecule drugs - UK's STORM Therapeutics, Microbiotica, Mironid, and Alchemab pulling in a combined $172 million - Netherlands' Laigo Bio adding $6 million Add OMass' $298 million, and that's roughly $704 million in new financing across Europe this year. The continent's biotech scene is clearly heating up. ### What's Next for OMass? The proceeds will primarily support OMS1620, a potential best-in-class MC2 receptor antagonist. It's headed into Phase 2 trials for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. These are serious conditions with limited treatment options, so a new approach could be a game-changer. "We see meaningful potential for OMS1620 to improve the treatment for patients with CAH," said Evan Greif, Principal at Bain Capital Life Sciences. "We look forward to partnering with Ros and the team to support the Company's strategic and patient-first approach." OMass was founded in 2016 as a spin-out from Professor Dame Carol Robinson's lab at the University of Oxford. Their work translates native mass spectrometry research into novel small molecule therapeutics. With this fresh capital, they're one step closer to bringing those therapies to patients who need them. Max Klement, Partner at Novo Holdings, added: "We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic."